lansoprazole + amoxicillin

Lansoprazole + amoxicillin is a combination of two pharmaceutical agents used primarily as part of multi-drug regimens for the eradication of Helicobacter pylori (H. pylori) infection, particularly in patients with duodenal ulcers. Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+, K+-ATPase enzyme system at the secretory surface of gastric parietal cells, thereby reducing stomach acidity and creating an environment less favorable for H. pylori survival. Amoxicillin is a penicillin-class antibiotic that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. This combination is often used alongside another antibiotic (commonly clarithromycin or metronidazole) as part of triple therapy regimens for H. pylori eradication[1][2][3][4].